Radiation Effective in Treating Early Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 13 No 10
Volume 13
Issue 10

Large Study Confirms Radiation therapy not only destroys prostate cancer in patients with early disease but keeps it from returning, a very large study of patients from six medical centers has found.

Large Study Confirms Radiation therapy not only destroys prostate cancer in patients with early disease but keeps it from returning, a very large study of patients from six medical centers has found.

“The study confirms and elaborates on what has been reported before by individual medical centers: radiation therapy is an effective means to treat localized (stage T1B, T1C, or T2) tumors,” said lead author William U. Shipley, MD, of Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts.

“The multicenter nature of this study shows that previous studies using smaller numbers of patients at individual medical centers can be widely generalized,” said Anthony Zietman, md, also of Massachusetts General Hospital and Harvard Medical School.

Five-Year Follow-up Finds Patients Disease Free

All patients in the study received external-beam radiation therapy only and were followed after treatment with regular prostate-specific antigen (PSA) blood tests. The study found that 81% of patients who had a low pretreatment PSA level (less than 10 ng/mL) had no evidence of disease (ie, no consecutive rises in PSA levels) 5 years following radiation treatments. In addition, 68% of patients with a pretreatment PSA level higher than 10 ng/mL but lower than 20 ng/mL were disease free at 5-year follow-up.

Related Videos
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Financial constraints and a lack of education among some patients and providers must be addressed to improve the real-world use of certain prostate cancer therapies, says Neeraj Agarwal, MD.
Novel anti-PSMA monoclonal antibody rosopatamab is capable of carrying a bigger payload of radiation particles, which may potentially reduce doses for patients with prostate cancer, says Neeraj Agarwal, MD.
Findings from recent studies support the use of artificial intelligence-based tools in the context of radiation therapy for patients with localized prostate cancer, according to Neeraj Agarwal, MD.
Germline testing may elucidate important mutations in patients with metastatic prostate cancer who may be eligible to receive treatment with PARP inhibitors, according to Neeraj Agarwal, MD.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Artificial intelligence programs may help introduce new care strategies that minimize the risk of adverse effects in patients with prostate cancer, according to Wayne G. Brisbane, MD.
An artificial intelligence algorithm appears to create accurate focal treatment margins in patients with prostate cancer, according to Wayne G. Brisbane, MD.
Artificial intelligence may be useful in screening for prostate cancer in patients with elevated prostate specific antigen levels who have undergone MRI, according to Wayne G. Brisbane, MD.
Related Content